Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs MorphoSys AG

Teva vs MorphoSys: A Decade of Cost Efficiency

__timestampMorphoSys AGTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014770009216000000
Thursday, January 1, 2015770008296000000
Friday, January 1, 20169700010044000000
Sunday, January 1, 20173300011560000000
Monday, January 1, 2018179662910558000000
Tuesday, January 1, 2019120851989351000000
Wednesday, January 1, 202091741468933000000
Friday, January 1, 2021322000008284000000
Saturday, January 1, 2022486200007952000000
Sunday, January 1, 2023583550008200000000
Monday, January 1, 20248480000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Cost Efficiency Over Time

In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis compares the cost of revenue efficiency between Teva Pharmaceutical Industries Limited and MorphoSys AG from 2014 to 2023. Teva, a global leader, consistently reported a cost of revenue exceeding $8 billion annually, peaking in 2017. In contrast, MorphoSys AG, a smaller biotech firm, showed a dramatic increase in cost efficiency, with costs rising from a modest $77,000 in 2014 to over $58 million by 2023. This represents a staggering growth of over 75,000% in less than a decade. While Teva's costs have shown a slight decline, MorphoSys's rapid expansion highlights its aggressive growth strategy. This comparison underscores the diverse strategies and challenges faced by pharmaceutical companies in managing their cost structures effectively.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025